Drug Profile
Research programme: targeted T cell therapeutics - Vor BioPharma
Alternative Names: VOR 101Latest Information Update: 28 Nov 2021
Price :
$50
*
At a glance
- Originator Vor Biopharma
- Class CAR-T cell therapies; Gene therapies; Immunotherapies
- Mechanism of Action Immunologic cytotoxicity; T lymphocyte replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 28 Nov 2021 No recent reports of development identified for preclinical development in Cancer in USA (Parenteral)
- 17 Oct 2017 Preclinical trials in Cancer in USA before October 2017 (PureTech Health pipeline, October 2017)
- 09 May 2016 Early research in Cancer in USA (unspecified route)